MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
PARP inhibition in cancer therapy
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,206 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,206 works in the cohort · of 4,299,418page 3 of 25

Labels cover 6 of 1,206 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,206 of 1,206 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.
Kim N., Dana E. Rathkopf, Matthew R. Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos +14 more
2022· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
125
citations
afffundunlabeled
Resistance to PARP-Inhibitors in Cancer Therapy
Alicia Montoni, Mihaela Robu, Émilie Pouliot, Girish M. Shah
2013· article· en· Frontiers in Pharmacology· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
101
citations
affunlabeled
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors
Timothy A. Yap, Aditya Bardia, Michael Dvorkin, Matthew D. Galsky, J. Thaddeus Beck, David R. Wise +14 more
2022· letter· en· JAMA Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · none
100
citations
affunlabeled
Niacin and Carcinogenesis
James B. Kirkland
2003· review· en· Nutrition and Cancer· Medicine
distilled prediction:candidate · noneconsensus · none
95
citations
affunlabeled
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
Bradley J. Monk, Robert L. Coleman, Keiichi Fujiwara, Michelle Wilson, Amit M. Oza, Ana Oaknin +15 more
2021· article· en· International Journal of Gynecological Cancer· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
91
citations
affunlabeled
Homologous Recombination Deficiency in Breast Cancer: A Clinical Review
Wendie Den Brok, Kasmintan A. Schrader, Sophie Sun, Anna V. Tinker, Eric Y. Stutheit-Zhao, Samuel Aparício +1 more
2017· review· en· JCO Precision Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · none
89
citations

How this was built: Screen · Findings · About